RAPP

Current Thesis

Precision-neuroscience small-cap whose lead asset RAP-219 (TARPγ8-selective AMPAR modulator) posted a 77.8% median clinical-seizure reduction + 24% seizure-freedom rate in the Dec-2025 Phase 2a focal-onset-seizure (FOS) readout — class-leading numbers that pulled the Phase 3 start forward to Q2 2026. Narrative is ACCELERATING (stock 5× off $7.73 low, now $39.71 near $42.27 high; Raymond James initiation 2026-04-10; Truist upgrade to Strong-Buy 2026-03-25; Tenacia China deal with $20M upfront + $308M bio-bucks). But the near-term setup is a binary — AAN 8-week follow-up podium on 2026-04-21 15:54 CDT, i.e. <24h out. Don't buy 1 day before a clinical data print at the 52-wk-high.

Bull Case

• Phase 2a FOS efficacy was not ambiguous: 77.8% median clinical-seizure reduction, 24% seizure freedom, 8-week window, topline disclosed Dec 2025 — this is Vimpat/Briviact-killing magnitude if it replicates in Phase 3.
• Accelerated Phase 3 start Q2 2026 announced post End-of-Phase-2 FDA alignment (investor PR, "Accelerated Initiation of RAP-219 Phase 3 Program") — removes the "registrational design unclear" overhang that capped the multiple pre-Dec-2025.
• Tenacia Greater-China collaboration: $20M cash upfront + up to ~$308M milestones — non-dilutive validation, reduces Phase 3 dilution risk.
• Cash $490.5M (end-2025) vs. our prior dossier's $280M stale figure — runway guided into H2 2029, covers Phase 3 enrollment without forced raise.
• Sell-side velocity: 5 covering analysts, consensus Strong-Buy, avg PT $46.6. Raymond James init 2026-04-10, Truist upgrade 2026-03-25, Rapport's own AAN-data push 2026-04-13 — classic narrative-acceleration window where upgrades cluster 14d pre-catalyst.
• Platform optionality intact: bipolar-mania Phase 2 topline H1 2027, long-acting injectable progressing, PGTCS expansion — four separate binary shots once FOS proves out.
• Takeout profile: γ8-selective (avoids Fycompa whole-brain AMPA tox), Atlas/Third Rock cap table, $1.9B market cap — classic mid-cycle neuro M&A target (cf. Karuna/BMS, Cerevel/Abbvie).

Bear Case

• Binary-catalyst in <24h: AAN podium 2026-04-21 15:54 CDT is an 8-week follow-up to the Dec-2025 headline. If durability fades (seizure-reduction median drops materially from 77.8%, or tolerability signal emerges at 8wk), stock gaps -30% minimum. Headline was already priced in; asymmetry is negative at $39.71.
• Stretched tape: $39.71 vs. 52-wk high $42.27 = only 6% below peak; stock is 5.1× off the $7.73 low. Narrative-momentum buyers who entered [entry redacted]-25 have +60-160% paper PnL — motivated sellers into any disappointing print.
• Platform = one molecule: a single tox/hepatic/CV SAE in any indication kills FOS + bipolar + pNP + trigeminal simultaneously. Correlation across the four shots-on-goal is ≈1.
• Opex ~$30M/quarter accelerating as Phase 3 ramps; bipolar mania topline isn't until H1 2027 — long data-gap after AAN.
• Small-cap biotech beta: XBI ±20% moves unrelated to RAPP pipeline; crowded hedge-fund long per hedge-fund 13F clustering typical for post-POC neuro names.
• Mean-reversion risk: RSI likely >70 entering AAN (5× run in 10 months), short interest probably bled out — no short-squeeze fuel left if data is merely "in-line".

Setup & Price Structure

• Last: $39.71 (2026-04-17 close)
• 52-wk range: $7.73 — $42.27 (current is 513% off low, 6% below high)
• Market cap: ~$1.9B
• Cash: $490.5M (Dec-2025), runway into H2 2029
• IPO: Jun 2024 at $17 (current 2.3× IPO)
• Tape character: near-vertical April rally into AAN, classic catalyst run-up. Missing fields next pass: 20/50/200-DMA exact levels, RSI, IV rank, options skew into 2026-04-21. TODO capture on next price-context pull. Rough 20-EMA estimate in $32-34 zone given rally slope.
• Structure read: an entry HERE (pre-AAN) is not a trend-follower's entry — it's a lottery ticket on 8wk durability data. Clean re-entry setup would be: post-AAN positive reaction, consolidation 2-3 weeks, higher-low at prior breakout, then initiate.

Catalyst Calendar (next 30 days)

• 2026-04-21 15:54 CDT — AAN 2026 podium presentation, RAP-219 Phase 2a FOS 8-week follow-up efficacy + tolerability + RNS long-episode biomarker (William W. Motley MD). BINARY. <24h from dossier time.
• ~2026-04-21 to 2026-05-05 — Post-AAN investor calls, sell-side model updates, potential guidance on Phase 3 trial design (enrollment start, N, primary endpoint).
• Q2 2026 (by 2026-06-30) — RAP-219 Phase 3 FOS program initiation (company-guided "accelerated"). First-patient-in press release is a mini-catalyst.
• ~2026-05-07 to 2026-05-14 — Q1 2026 earnings print (est.). Watch: cash burn, Phase 3 capex guide, any Tenacia milestone recognition. Note: last print was Q4 2025 on 2026-03-17 (already passed).
• Rolling — 8-K on any RAP-219 safety/SAE event (bearish trigger, see below).

What Would Change Our Mind

• APPROVE (post-AAN green, small): AAN 8wk data confirms durability (seizure reduction holds >65% median, seizure-freedom >20%, no new tox signal) → stock gaps +10-20%, then watch for 3-7 day consolidation + reclaim of intraday high → probe [trade redacted] of book at break of post-AAN consolidation high, stop under post-AAN gap-fill low.
• APPROVE (SUPREME size): Phase 3 FOS first-patient-in announced Q2 2026 with aggressive enrollment guide + a second analyst upgrade cluster → size up to 3-5%. This is the "Phase 3 design de-risked" inflection.
• DEFER (now): Entry at [entry redacted] pre-AAN is a binary coin-flip, not narrative-momentum. Wait for the print, let tape show its hand, enter on confirmed reaction.
• SKIP / SHORT SIGNAL: AAN data disappoints (durability fades, tolerability issue, RNS biomarker doesn't corroborate clinical seizure numbers), stock gaps down → do NOT buy the dip. Correlation across 4 programs is 1; this is thesis-breaking, not a discount.
• Hard bearish invalidation: Any 8-K disclosing SAE, hepatic signal, or clinical-hold on RAP-219 in any indication → platform NPV collapses, target = cash-value band (~$490M / ~48M shares ≈ $10 floor). Stop out immediately, no averaging down.
• Weekly close below 20-EMA (rough $32-34) → trend break, trim/exit even if narrative intact.
• Bipolar-mania or pNP Phase 2 primary-endpoint miss (2026-H2 / 2027-H1) → platform premium evaporates to single-indication epilepsy NPV; re-rate lower.

Correlation Notes

Moves with: PRAX (neurology small-cap, epilepsy/movement), SAGE (CNS small-cap, GABA/AMPA-adjacent), NRXS (neuroscience small-cap), LXRX (CNS-adjacent small-cap), LQDA/DNLI (mid-cap neuro beta). Sector factor = XBI — don't stack RAPP with another XBI-beta binary in the same catalyst week (i.e. don't pair with another clinical-readout long into 2026-04-21). All four RAP-219 indications are the same molecule — "internal diversification" is illusory; SAE is correlation-1 across programs. If already long RAPP, avoid adding NRXS/PRAX/SAGE in same week for portfolio-level concentration reasons; single-factor XBI shock is the real risk.